Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus-Reference-Cited by-同舟云学术

Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus

Published:2017-12-05 Issue:4 Volume:20 Page:812-820
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Inagaki Nobuya¹^ORCID,Harashima Shin-ichi¹^ORCID,Kaku Kohei²^ORCID,Kondo Kazuoki³,Maruyama Nobuko³,Otsuka Makiko³,Kawaguchi Yutaka³,Iijima Hiroaki³^ORCID

Affiliation:

1. Department of Diabetes, Endocrinology and Nutrition; Kyoto University Graduate School of Medicine; Kyoto Japan

2. Department of General Internal Medicine 1; Kawasaki Medical School; Okayama Japan

3. Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma Corporation; Tokyo Japan

Funder

Mitsubishi Tanabe Pharma Corp.

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.13152/fullpdf

Reference36 articles.

1. International Diabetes Federation Diabetes Atlas 7th http://www.diabetesatlas.org/resources/2015-atlas.html

2. 10-year follow-up of intensive glucose control in type 2 diabetes;Holman;N Engl J Med,2008

3. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients;Shichiri;Diabetes Care,2000

4. Insulin therapy in people with type 2 diabetes: opportunities and challenges?;Home;Diabetes Care,2014

5. Hypoglycemia, diabetes, and cardiovascular events;Desouza;Diabetes Care,2010

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy;Communications Biology;2023-09-08

2. Efficacy and safety of empagliflozin in combination with insulin in Chinese patients with type 2 diabetes and insufficient glycaemic control: A phase III, randomized, double‐blind, placebo‐controlled, parallel study;Diabetes, Obesity and Metabolism;2023-03-23

3. Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations;Diabetes & Metabolism Journal;2020

4. Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial;Diabetes, Obesity and Metabolism;2019-12-20

5. Identification of subgroups of patients with type 2 diabetes with differences in renal function preservation, comparing patients receiving sodium‐glucose co‐transporter‐2 inhibitors with those receiving dipeptidyl peptidase‐4 inhibitors, using a supervised machine‐learning algorithm (PROFILE study): A retrospective analysis of a Japanese commercial medical database;Diabetes, Obesity and Metabolism;2019-08